Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Smith

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
The Lancet. Gastroenterology & Hepatology|February 12, 2020
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trialEric Rullier, Véronique Vendrely, Julien Asselineau, et al.
The Lancet. Oncology|April 15, 2022
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A Diaz, Kai-Keen Shiu, Tae-Won Kim, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
The Lancet. Oncology|April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialThierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
Journal of Health, Population, and Nutrition|February 7, 2026
Real-time public health interventions driven by wastewater and environmental surveillance during Uganda's 2025 martyrs day mass gatheringAndrew Nsawotebba, Susan Nabadda, Noah Hull, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Gastroenterology & Hepatology|February 12, 2020
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trialEric Rullier, Véronique Vendrely, Julien Asselineau, et al.
The Lancet. Oncology|April 15, 2022
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A Diaz, Kai-Keen Shiu, Tae-Won Kim, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
The Lancet. Oncology|April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialThierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
Journal of Health, Population, and Nutrition|February 7, 2026
Real-time public health interventions driven by wastewater and environmental surveillance during Uganda's 2025 martyrs day mass gatheringAndrew Nsawotebba, Susan Nabadda, Noah Hull, et al.
Pageof 10